Raymond James analyst John Ransom raised the firm’s price target on Tenet Healthcare (THC) to $250 from $200 and keeps an Outperform rating on the shares. The firm said Q3 results exceeded expectations, as the company reported above-Street adjusted EBITDA. The quarter did benefit from a $38M out of period direct payment program, so the core beat was closer to roughly $23M all attributable to the hospital division, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $260 from $238 at UBS
- Tenet Healthcare price target raised to $232 from $225 at Morgan Stanley
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare